|
gptkbp:instanceOf
|
gptkb:chemical_compound
gptkb:drug
|
|
gptkbp:ATCCode
|
none
|
|
gptkbp:CASNumber
|
1801633-27-3
|
|
gptkbp:clinicalTrialPhase
|
Phase 3 (as of 2023)
|
|
gptkbp:developedBy
|
gptkb:Incyte_Corporation
|
|
gptkbp:eliminatedIn
|
hepatic
|
|
gptkbp:hasMolecularFormula
|
C22H17ClN6O2S
|
|
gptkbp:hasSMILES
|
CN1C=NN=C1C2=NC3=CC(=C(C=C3N=C2C4=CC=C(C=C4)Cl)OC)N5CCSCC5=O
|
|
gptkbp:hasUNII
|
6Q1K1VJ0ZV
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
parsaclisib
|
|
gptkbp:indication
|
gptkb:mantle_cell_lymphoma
gptkb:marginal_zone_lymphoma
leukemia
chronic lymphocytic leukemia
follicular lymphoma
|
|
gptkbp:IUPACName
|
5-(1,1-dioxo-1,4-thiazinan-4-yl)-8-methoxy-2-(1-methyl-1H-pyrazol-4-yl)-3-(4-chlorophenyl)imidazo[1,2-a]pyrazine
|
|
gptkbp:legalStatus
|
not approved (as of 2023)
|
|
gptkbp:mechanismOfAction
|
gptkb:PI3Kδ_inhibitor
|
|
gptkbp:molecularWeight
|
464.93 g/mol
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL3989989
91827377
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
diarrhea
infections
rash
neutropenia
|
|
gptkbp:status
|
investigational
|
|
gptkbp:synonym
|
gptkb:INCB-50465
gptkb:INCB050465
gptkb:INCB50465
|
|
gptkbp:target
|
gptkb:PI3K_delta
|
|
gptkbp:bfsParent
|
gptkb:PIK3CD
|
|
gptkbp:bfsLayer
|
5
|